Compare WMS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMS | ROIV |
|---|---|---|
| Founded | 1966 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 14.1B |
| IPO Year | 2014 | N/A |
| Metric | WMS | ROIV |
|---|---|---|
| Price | $149.23 | $21.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $157.80 | $21.94 |
| AVG Volume (30 Days) | 600.3K | ★ 6.5M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.86 | N/A |
| Revenue | ★ $2,986,560,000.00 | $20,329,000.00 |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | $7.01 | $376.94 |
| P/E Ratio | $25.54 | ★ N/A |
| Revenue Growth | ★ 2.48 | N/A |
| 52 Week Low | $93.92 | $8.73 |
| 52 Week High | $155.39 | $22.45 |
| Indicator | WMS | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 53.39 | 68.21 |
| Support Level | $144.67 | $20.14 |
| Resistance Level | $150.10 | $21.48 |
| Average True Range (ATR) | 4.05 | 0.66 |
| MACD | -0.28 | -0.02 |
| Stochastic Oscillator | 44.31 | 87.12 |
Advanced Drainage Systems Inc is the manufacturer of water management solutions in the stormwater and onsite septic wastewater industries, providing superior drainage solutions for use in the construction and agriculture marketplaces. Its products are used across a broad range of end markets and applications, including residential, non-residential, infrastructure and agriculture applications. It operates business in three distinct reportable segments: Pipe; International, and Infiltrator. It generates a greater proportion of revenue from its Pipe segment, which consists of Pipe product sales in the United States. The Infiltrator is a provider of plastic leachfield chambers and systems, septic tanks and accessories, for use in residential applications.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.